WO2008066755A3 - Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents - Google Patents
Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents Download PDFInfo
- Publication number
- WO2008066755A3 WO2008066755A3 PCT/US2007/024319 US2007024319W WO2008066755A3 WO 2008066755 A3 WO2008066755 A3 WO 2008066755A3 US 2007024319 W US2007024319 W US 2007024319W WO 2008066755 A3 WO2008066755 A3 WO 2008066755A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tyrosine kinase
- apicomplexan
- kinase inhibitors
- kinetolastid
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid or apicomplexan protozoan with tyrosine kinase inhibitors.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/446,286 US8338433B2 (en) | 2006-11-22 | 2007-11-21 | Tyrosine kinase inhibitors as anti-kinetoplastid agents |
EP07867556A EP2088863A2 (en) | 2006-11-22 | 2007-11-21 | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
CA002669531A CA2669531A1 (en) | 2006-11-22 | 2007-11-21 | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
US13/676,326 US9545410B2 (en) | 2006-11-22 | 2012-11-14 | Tyrosine kinase inhibitors as anti-kinetoplastid agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86071706P | 2006-11-22 | 2006-11-22 | |
US60/860,717 | 2006-11-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/446,286 A-371-Of-International US8338433B2 (en) | 2006-11-22 | 2007-11-21 | Tyrosine kinase inhibitors as anti-kinetoplastid agents |
US13/676,326 Division US9545410B2 (en) | 2006-11-22 | 2012-11-14 | Tyrosine kinase inhibitors as anti-kinetoplastid agents |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008066755A2 WO2008066755A2 (en) | 2008-06-05 |
WO2008066755A3 true WO2008066755A3 (en) | 2009-01-15 |
Family
ID=39468473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/024319 WO2008066755A2 (en) | 2006-11-22 | 2007-11-21 | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
Country Status (4)
Country | Link |
---|---|
US (2) | US8338433B2 (en) |
EP (1) | EP2088863A2 (en) |
CA (1) | CA2669531A1 (en) |
WO (1) | WO2008066755A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8246966B2 (en) | 2006-08-07 | 2012-08-21 | University Of Georgia Research Foundation, Inc. | Trypanosome microsome system and uses thereof |
WO2008066755A2 (en) | 2006-11-22 | 2008-06-05 | University Of Georgia Research Foundation, Inc. | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
US8916574B2 (en) * | 2009-09-28 | 2014-12-23 | Qilu Pharmaceutical Co., Ltd. | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
US9765037B2 (en) | 2010-01-28 | 2017-09-19 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases |
EP2528919B1 (en) * | 2010-01-28 | 2016-11-02 | University of Washington | Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases |
CN102766209B (en) * | 2012-07-04 | 2014-09-10 | 中国检验检疫科学研究院 | Monoclonal antibody of anti-perkinsus membrane protein, preparation method and application thereof |
KR101441096B1 (en) | 2012-11-27 | 2014-09-25 | 가톨릭대학교 산학협력단 | Composition for preventing and treating Toxoplasma gondii infection comprising gefitinib |
US9518026B2 (en) | 2013-05-20 | 2016-12-13 | University Of Washington Through Its Center For Commercialization | 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum |
CN105377262A (en) * | 2013-07-11 | 2016-03-02 | 普雷西恩护肤公司 | Topical treatment of localized scleroderma |
KR101508611B1 (en) * | 2013-09-02 | 2015-04-08 | 가톨릭대학교 산학협력단 | Composition for preventing and treating Toxoplasma gondii infection comprising afatinib |
KR101508610B1 (en) * | 2013-09-02 | 2015-04-08 | 가톨릭대학교 산학협력단 | Composition for preventing and treating Toxoplasma gondii infection comprising dacomitinib |
KR101540739B1 (en) | 2013-09-02 | 2015-08-05 | 가톨릭대학교 산학협력단 | Composition for preventing and treating Toxoplasma gondii infection comprising pelitinib |
WO2015030504A1 (en) * | 2013-09-02 | 2015-03-05 | 가톨릭대학교 산학협력단 | Pharmaceutical composition for prevention or treatment of toxoplasmosis, comprising anti-non-small cell lung cancer agent as active ingredient |
KR101538385B1 (en) * | 2013-09-02 | 2015-07-29 | 가톨릭대학교 산학협력단 | Composition for preventing and treating Toxoplasma gondii infection comprising crizotinib |
WO2015103026A2 (en) * | 2014-01-03 | 2015-07-09 | The Regents Of The University Of Michigan | Treatment of neurological disorders |
PT3134119T (en) * | 2014-04-24 | 2018-11-07 | Pfizer | Cancer treatment |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030059862A1 (en) * | 2001-05-24 | 2003-03-27 | Ruben Steven M. | Antibodies against tumor necrosis factor delta (APRIL) |
US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
US20030203846A1 (en) * | 2002-04-25 | 2003-10-30 | Srivastava Pramod K. | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
WO2008006085A2 (en) * | 2006-07-07 | 2008-01-10 | University Of Washington | Compositions and methods for predicting inhibitors of protein targets |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3470182A (en) | 1967-02-09 | 1969-09-30 | Sandoz Ag | 4-amino-substituted quinazolines |
US3551427A (en) | 1969-05-09 | 1970-12-29 | Sandoz Ag | 4-thienyl-2-(1h)-quinazolones |
FR2077803B1 (en) | 1970-02-16 | 1973-03-16 | Innothera Lab Sa | |
US3800039A (en) | 1970-10-21 | 1974-03-26 | Mead Johnson & Co | Antithrombogenic process employing substituted 6,7-dialkoxyquinazolines |
JPS5538325A (en) | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
US5618829A (en) | 1993-01-28 | 1997-04-08 | Mitsubishi Chemical Corporation | Tyrosine kinase inhibitors and benzoylacrylamide derivatives |
KR960703622A (en) | 1993-07-15 | 1996-08-31 | 수잔 포오덴 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
EP0892789B2 (en) | 1996-04-12 | 2009-11-18 | Warner-Lambert Company LLC | Irreversible inhibitors of tyrosine kinases |
CO4940418A1 (en) | 1997-07-18 | 2000-07-24 | Novartis Ag | MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
JP4249295B2 (en) * | 1998-09-17 | 2009-04-02 | ソフタード工業株式会社 | Apparatus for extracting catalyst in reaction tower and method for extracting catalyst |
WO2000038519A1 (en) | 1998-12-31 | 2000-07-06 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
CA2383546A1 (en) | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
JP2003503354A (en) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | SRC kinase inhibitor compounds |
KR20020027635A (en) | 1999-09-10 | 2002-04-13 | 폴락 돈나 엘. | Tyrosine kinase inhibitors |
JP2003512353A (en) | 1999-10-19 | 2003-04-02 | メルク エンド カムパニー インコーポレーテッド | Tyrosine kinase inhibitor |
DE60017179T2 (en) | 1999-10-19 | 2006-01-05 | Merck & Co., Inc. | TYROSINE KINASEINHIBITORS |
US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US7550558B2 (en) | 2001-06-01 | 2009-06-23 | Fundacao De Ampara A Pesquiso Do Estado De Sao Paolo (Fapesp) | Antimicrobial peptides and methods for identifying and using such peptides |
ES2255621T3 (en) | 2001-06-22 | 2006-07-01 | MERCK & CO., INC. | THYROSINE KINASE INHIBITORS. |
WO2003011836A1 (en) | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003020276A1 (en) | 2001-08-30 | 2003-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US8246966B2 (en) | 2006-08-07 | 2012-08-21 | University Of Georgia Research Foundation, Inc. | Trypanosome microsome system and uses thereof |
WO2008021092A2 (en) | 2006-08-07 | 2008-02-21 | University Of Georgia Research Foundation, Inc. | Trypanosome microsome system and uses thereof |
WO2008066755A2 (en) | 2006-11-22 | 2008-06-05 | University Of Georgia Research Foundation, Inc. | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
-
2007
- 2007-11-21 WO PCT/US2007/024319 patent/WO2008066755A2/en active Application Filing
- 2007-11-21 EP EP07867556A patent/EP2088863A2/en not_active Withdrawn
- 2007-11-21 US US12/446,286 patent/US8338433B2/en not_active Expired - Fee Related
- 2007-11-21 CA CA002669531A patent/CA2669531A1/en not_active Abandoned
-
2012
- 2012-11-14 US US13/676,326 patent/US9545410B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
US20030059862A1 (en) * | 2001-05-24 | 2003-03-27 | Ruben Steven M. | Antibodies against tumor necrosis factor delta (APRIL) |
US20030203846A1 (en) * | 2002-04-25 | 2003-10-30 | Srivastava Pramod K. | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
WO2008006085A2 (en) * | 2006-07-07 | 2008-01-10 | University Of Washington | Compositions and methods for predicting inhibitors of protein targets |
Non-Patent Citations (1)
Title |
---|
GEORGE T.G.: "Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sufonamides and benzamides", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 14, 2006, pages 5699 - 5710, XP025133473 * |
Also Published As
Publication number | Publication date |
---|---|
CA2669531A1 (en) | 2008-06-05 |
US20130072484A1 (en) | 2013-03-21 |
EP2088863A2 (en) | 2009-08-19 |
WO2008066755A2 (en) | 2008-06-05 |
US9545410B2 (en) | 2017-01-17 |
US20100311742A1 (en) | 2010-12-09 |
US8338433B2 (en) | 2012-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008066755A3 (en) | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents | |
WO2008054599A3 (en) | Rho kinase inhibitors | |
WO2007079164A3 (en) | Protein kinase inhibitors | |
WO2009006389A3 (en) | Pyrimidine derivatives useful as raf kinase inhibitors | |
IL181811A (en) | Trifluoromethyl substituted phenylaminopyrimidines as inhibitors of bcr-abl kinase | |
WO2007115289A3 (en) | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer | |
EP2063882A4 (en) | Tyrosine kinase inhibitors for prevention or treatment of infection | |
WO2006034113A3 (en) | Quinolone analogs as cell proliferation inhibitors | |
WO2008005457A3 (en) | Pyridinonyl pdk1 inhibitors | |
WO2008127226A3 (en) | P13 kinase antagonists | |
WO2008127275A3 (en) | Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof | |
WO2008067121A3 (en) | Methods of treating cognitive impairment and dementia | |
WO2008011557A3 (en) | Heteroaryl inhibitors of rho kinase | |
WO2006050109A3 (en) | Novel kinase inhibitors | |
WO2007087245A3 (en) | Ret tyrosine kinase inhibition | |
EP2497470B8 (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors | |
WO2007025247A3 (en) | Transglutaminase inhibitors and methods of use thereof | |
UA85505C2 (en) | Kinase inhibitors | |
WO2006078287A3 (en) | Pde4b inhibitors and uses therefor | |
WO2006065928A3 (en) | Retention and drainage aids | |
WO2011031896A3 (en) | Pi3 kinase inhibitors and uses thereof | |
WO2007126883A3 (en) | Surveying sterilizer methods and systems | |
WO2010065898A3 (en) | Egfr kinase knockdown via electrophilically enhanced inhibitors | |
WO2007081740A3 (en) | Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers | |
EP1948168A4 (en) | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07867556 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007867556 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2669531 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12446286 Country of ref document: US |